SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Len who wrote (825)11/30/1998 10:20:00 PM
From: Wally  Read Replies (1) of 998
 
Len: No. It's not a rejection. To the best of my knowledge Myotrophin's in a holding pattern with the FDA, waiting for rescheduling. Both sides need to get their collective act together.
In the final analysis I believe that it's the "trophy" in Myotrophin that makes it so important to Cephalon. It has never been a drug that was going to bring Cephalon to riches - not enough victims to make them wealthy. But it would help put Cephalon on the Bio Map.
Because of the hopelessness of the disease and the future improvements in Cephalon's pitching capabilities, I think Myotrophin will eventually pass through the FDA - of course, only after thousands of people suffer needlessly. If Myotrophin passes through the FDA within the next 6 months the timing of such success would have a very positive effect on the rest of the Cephalon pipeline. Could happen. Don't bet the ranch - but don't bet against it either.
Wally
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News